Language Select
Varian Logo

Press Releases

February 22, 2018
Varian (NYSE: VAR) today announced its ARIA® oncology information system has achieved Office of the National Coordinator for Health Information Technology (ONC-Health IT) 2015 Edition Health IT... Read more
February 22, 2018
Varian (NYSE: VAR) today announced it has acquired privately-held Montreal-based Evinance Innovation, Inc., a clinical decision support (CDS) software company. This acquisition expands the... Read more
February 20, 2018
Varian (NYSE: VAR) today announced three of its cancer care solutions have been named Category Leaders in the 2018 Best in KLAS: Software and Services Report by KLAS, an independent research firm... Read more
February 06, 2018
Varian (NYSE: VAR) today announced the Halcyon™ cancer treatment platform has received Atomic Energy Regulatory Board (AERB) Certificate for Import and Supply in India. This registration allows... Read more
February 05, 2018
Varian (NYSE: VAR) today announced it has acquired privately-held Mobius Medical Systems®, a leader in radiation oncology Quality Assurance (QA) software. This acquisition expands Varian's... Read more
January 29, 2018
Varian (NYSE: VAR) today announced that it will webcast a conference call to discuss the details of the agreement, also announced today, to acquire all the outstanding shares of Sirtex Medical... Read more
January 29, 2018
Varian Medical Systems (NYSE: VAR) today announced it has signed an agreement to acquire all the outstanding shares of Sirtex Medical Limited (ASX: SRX) ("Sirtex"), an Australia-based global life... Read more
January 25, 2018
Highlighting the growing adoption of proton therapy systems for the treatment of cancer, Varian (NYSE: VAR) today announced it has reached an agreement with Sylvester Comprehensive Cancer Center... Read more
January 24, 2018
Varian (NYSE: VAR) today announced it has been selected by Proton International to install a Varian ProBeam® Compact single-room proton therapy system in the new University of Alabama at... Read more
January 24, 2018
First Quarter 2018 Summary Revenues of $679 million grew 13 percent Oncology gross orders grew 7 percent; booked 2 new Proton orders GAAP operating earnings of 17.9 percent of revenues; Non-GAAP... Read more

Corporate Communications Contact

Mark Plungy
Director, Public Relations
650.424.5630
[email protected]

Investor Relations Contact

Mike Bruff
SVP, Investor Relations
650.424.5163
[email protected]

Monica Prokocki
Director, Investor Relations
650.424.5184
[email protected]